Prior authorization: none stated

No prior authorization requirements are stated in this policy document section. The policy text explicitly indicates that there are no prior authorization statements present in this part of the document.

Utilization implied — justification may be required

Although the policy does not establish a formal prior authorization program for pancreatic enzyme testing, the document highlights overutilization concerns and implies that justification may be required for repeat or concurrent testing; utilization management actions could be applied based on clinical appropriateness.

• Policy notes routine overuse of lipase in ED and inpatient settings and associated unnecessary costs and investigations.
• Text indicates no explicit prior authorization but suggests payer may require justification for repeat or concurrent amylase/lipase testing.

Procedure codes referenced — subject to plan rules

The policy lists specific CPT procedure codes for reference; any plan-level prior-authorization requirements would apply to these codes per plan rules.

• Referenced CPT codes include 82150 (amylase) and 83690 (lipase) among others (83519, 83520, 83529, 84145, 86140, 86141).

Coding update — CPT 86141 added (no PA specified)

The policy does not state a prior authorization requirement, but the coding list was updated to add CPT 86141 (hsCRP); providers should note this added code in billing/coding references.

• Revision history documents addition of CPT code 86141 to the policy coding list.

Step therapy: none specified

No step therapy requirements are specified in the policy; the document explicitly states that no step therapy is included in this portion of the policy.

Prefer lipase-first; avoid routine co-ordering with amylase

The policy and cited evidence favor ordering lipase alone rather than both lipase and amylase; when considering sequencing, clinicians should order lipase first and avoid routine co-ordering of amylase.

• Multiple studies and cost analyses show lipase provides better sensitivity/specificity and cost savings if amylase is omitted.
• AACC guidance: do not order amylase if serum lipase is available; discourage routine ordering of both tests.

Preferred-test first: serum lipase preferred

Professional guidance recommends preferring serum lipase over amylase for initial diagnosis and discourages routine ordering of both tests when lipase is available as a stat test.

• AACC: 'do not order this test if serum lipase test is available' and discourages testing both amylase and lipase.

Policy consolidation note

Policy items consolidated — see other provider-action callouts for explicit requirements on ordering, documentation, coding, and sequencing.

Required clinical documentation — document presenting signs/symptoms

Orders for serum lipase should be accompanied by clinical documentation that supports signs and symptoms of acute pancreatitis (e.g., epigastric/upper abdominal pain, nausea/vomiting, abdominal tenderness, fever, tachycardia, hypotension, Cullen/Grey Turner signs).

• Note 1 lists acceptable signs and symptoms that should be documented when ordering serum lipase.

Clinical documentation for enzyme testing — record diagnostic rationale

When ordering pancreatic enzyme testing, document the clinical presentation and diagnostic rationale (e.g., characteristic abdominal pain, suspected acute pancreatitis, relevant imaging findings); Atlanta classification (>=3x URL) is cited as part of diagnostic criteria.

• Document if enzyme elevation is being used toward the Atlanta criteria (≥3× URL) as part of diagnosis.
• Include imaging results or clinical features when relevant to support medical necessity.

Regulatory note — follow LCD/NCD and CLIA for LDTs

If there is a conflict between this policy and applicable government coverage (LCD/NCD), government policy supersedes; laboratories performing LDTs must comply with CLIA high-complexity validation and documentation requirements.

• Policy disclaimer references LCD/NCD precedence for Medicare/Medicaid determinations.
• LDTs are regulated under CLIA as high-complexity tests and must be validated and documented accordingly.

Documentation expectations — signs/symptoms and frequency limits

Providers should document signs and symptoms of acute pancreatitis per Note 1 and adhere to the policy's frequency limits (e.g., no more than one serum lipase test per day in the outpatient setting).

• Revision history operationalized frequency: '(no more than one test per day in the outpatient setting)'.
• Note 1 enumerates signs and symptoms expected to be documented.

Denial risk — tests without supporting symptoms may be denied

Requests for serum lipase (or amylase) ordered without documentation of presenting signs or symptoms of acute pancreatitis — or for situations not described in the policy — may be denied as not meeting coverage criteria.

• 09/01/2023 revision language: serum lipase and/or amylase DOES NOT MEET COVERAGE CRITERIA for individuals with established acute or chronic pancreatitis, more than once per visit, or for asymptomatic individuals.
• Policy III.5 states measurement of serum lipase for other situations not described does not meet coverage criteria.

Overutilization risk — order only when clinically indicated

Ordering lipase or amylase tests in patients without abdominal pain or without clinical indication is described as overutilization and may trigger utilization management, additional testing, or denials.

• El Halabi (2019) documents overuse in ED leading to unnecessary imaging and consultations and associated costs.
• Ritter et al. (2019) estimate substantial national variable costs from unnecessary serial/concurrent testing.

Coding-related denial risk — claims reviewed vs listed CPT codes

Claims may be reviewed against the policy's listed CPT procedure codes (e.g., 82150 for amylase and 83690 for lipase); tests performed outside stated indications or for repetitive monitoring may be subject to denial or coding review.

• Coding list includes 82150 (amylase) and 83690 (lipase) among other assay codes; the policy notes codes are for reference and claims may be reviewed against listed codes.

Situations likely to be denied — established disease, repeat, or screening tests

Situations previously identified as not meeting coverage criteria — including testing in individuals with an established diagnosis of acute or chronic pancreatitis, testing more than once per visit, or testing asymptomatic individuals during a general exam — are likely to be denied.

• Revision history and policy language explicitly list these scenarios as not meeting coverage criteria.

Include Note 1 clinical findings with orders

Orders for serum lipase should be accompanied by documentation of signs and symptoms consistent with acute pancreatitis (Note 1); the policy implies clinicians should order testing for symptomatic individuals to support coverage.

• Note 1 enumerates compatible signs/symptoms (epigastric pain, nausea/vomiting, abdominal tenderness, fever, etc.).
• CC1: 'For individuals presenting with signs and symptoms of acute pancreatitis (see Note 1), measurement of serum lipase... MEETS COVERAGE CRITERIA.'

Order only with clinical suspicion of AP

Order testing only when the clinical presentation suggests acute pancreatitis; documentation of symptoms and diagnostic rationale is recommended to avoid denials related to overuse.

• Guidelines (IAP/APA) require at least two of three diagnostic criteria (pain, enzyme ≥3× URL, imaging).
• Studies show frequent overuse in EDs when clinical suspicion is low.

Adhere to LCD/NCD; no clinician restriction

Follow applicable government policies (LCD/NCD) that supersede this policy when relevant; the policy does not restrict which clinician type may order testing.

• Policy disclaimer: applicable government policy will be used when conflicts exist (e.g., LCD/NCD for Medicare).

Order testing for symptomatic patients only

Testing is expected to be ordered for symptomatic individuals per Note 1; the policy historically notes that testing for established disease or asymptomatic screening does not meet coverage criteria.

• Revision history and prior language clarify that testing for established acute/chronic pancreatitis or asymptomatic screening does not meet coverage criteria.